6185.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:08):

Stats
今日成交量	736 600
平均成交量	1.11M
市值	7.07B
EPS	HKD-0.580 ( 2023-10-30 )
下一个收益日期	( HKD0 ) 2024-06-28
Last Dividend	HKD0.937 ( 2022-07-13 )
Next Dividend	HKD0 ( N/A )
P/E	-3.35
ATR14	HKD0.0240 (0.11%)

音量相关性

長: 0.35 (neutral)

短: 0.62 (weak)

Signal:(63.984) Neutral

Cansino Biologics Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cansino Biologics Inc 相关性 - 货币/商品

0.29
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.29
( neutral )

-0.69
( moderate negative )

-0.63
( weak negative )

Cansino Biologics Inc 财务报表

Annual	2023
营收:	HKD345.18M
毛利润:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2023
营收:	HKD345.18M
毛利润:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2022
营收:	HKD1.03B
毛利润:	HKD-186.61M (-18.10 %)
EPS:	HKD-3.91

FY	2021
营收:	HKD4.30B
毛利润:	HKD3.00B (69.85 %)
EPS:	HKD7.74

Financial Reports:

No articles found.

Cansino Biologics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.937 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Cansino Biologics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.937	2022-07-13
Last Dividend	HKD0.937	2022-07-13
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	HKD0.937	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-03)

HKD0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6699.HK	Ex Dividend Knight	2023-07-03	Annually	0.00%
1899.HK	Ex Dividend Junior	2023-06-13	Annually	0.00%
0927.HK	Ex Dividend Knight	2023-08-29	Semi-Annually	0.00%
0052.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
2885.HK	Ex Dividend Junior	2023-06-15	Annually	0.00%
1480.HK	Ex Dividend Knight	2023-06-08	Sporadic	0.00%
0548.HK	Ex Dividend Junior	2023-05-19	Annually	0.00%
8092.HK	Ex Dividend Junior	2023-08-14	Sporadic	0.00%
2003.HK	Ex Dividend Junior	2023-10-17	Annually	0.00%
1072.HK	Ex Dividend Junior	2023-06-30	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-4.24	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.159	1.200	-5.30	-6.36	[0 - 0.3]
returnOnEquityTTM	-0.252	1.500	-3.91	-5.86	[0.1 - 1]
payoutRatioTTM	-0.0725	-1.000	-0.725	0.725	[0 - 1]
currentRatioTTM	1.999	0.800	5.01	4.00	[1 - 3]
quickRatioTTM	1.835	0.800	3.91	3.13	[0.8 - 2.5]
cashRatioTTM	0.790	1.500	6.72	10.00	[0.2 - 2]
debtRatioTTM	0.290	-1.500	5.17	-7.76	[0 - 0.6]
interestCoverageTTM	-37.09	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-3.62	2.00	-1.207	-2.41	[0 - 30]
freeCashFlowPerShareTTM	-6.10	2.00	-3.05	-6.10	[0 - 20]
debtEquityRatioTTM	0.512	-1.500	7.95	-10.00	[0 - 2.5]
grossProfitMarginTTM	-1.411	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-3.70	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.330	1.000	-2.95	-2.95	[0.2 - 2]
assetTurnoverTTM	0.0376	0.800	-3.08	-2.47	[0.5 - 2]
Total Score				-3.45

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.28	1.000	-0.433	0	[1 - 100]
returnOnEquityTTM	-0.252	2.50	-2.51	-5.86	[0.1 - 1.5]
freeCashFlowPerShareTTM	-6.10	2.00	-2.03	-6.10	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-3.62	2.00	-1.207	-2.41	[0 - 30]
payoutRatioTTM	-0.0725	1.500	-0.725	0.725	[0 - 1]
pegRatioTTM	0.116	1.500	-2.56	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-2.55	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.81

Cansino Biologics Inc

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.